. cis-regulatory elements (CREs) represent a highly enriched subset of the non-coding regions of the genome in which to search for such mutations. Here we use high-throughput chromosome conformation capture techniques (Hi-C) for 19,023 promoter fragments to catalog the regulatory landscape of colorectal cancer in cell lines, mapping CREs and integrating these with whole-genome sequence and expression data from The Cancer Genome Atlas 7, 8 . We identify a recurrently mutated CRE interacting with the ETV1 promoter affecting gene expression. ETV1 expression influences cell viability and is associated with patient survival. We further refine our understanding of the regulatory effects of copy-number variations, showing that RASL11A is targeted by a previously identified enhancer amplification 1 . This study reveals new insights into the complex genetic alterations driving tumor development, providing a paradigm for employing chromosome conformation capture to decipher non-coding CREs relevant to cancer biology.
The identification of driver mutations as opposed to passenger mutations is fundamental to understanding cancer and its response to therapy. With the large number of exome-sequenced tumors, all genes with coding changes that contribute substantially to tumorigenesis are likely to be cataloged soon. Motivated by the identification of recurrent mutations in regulatory elements in genes associated with oncogenesis, such as the TERT promoter 9, 10 , and TAL1 11 and PAX5 12 enhancers, efforts are now being directed to systematically analyze non-coding regions of cancer genomes for driver mutations [1] [2] [3] [4] [5] [6] . Although regional excess of somatic mutations is suggestive of positive selection in tumors, the size of the non-coding genome places a high burden on robustly establishing statistical significance. Coding regions provide obvious, discrete intervals in which to search for mutations, and it would be highly propitious to define similar functional elements for non-coding regions. CREs that modulate gene expression represent a highly enriched subset of the noncoding genome in which to search for driver mutations. However, these CREs can be highly tissue-specific, are often dispersed over long ranges, and only a small fraction of distal enhancers target the nearest transcript 8, 13 . The recent development of Hi-C has allowed researchers to map such regulatory regions, and importantly, link these to their respective target genes 8, [14] [15] [16] . Here we use capture Hi-C (CHi-C) for 19,023 promoter fragments to catalog the CRE landscape of colorectal cancer (CRC), identifying putative enhancers 8, 16 . Using these data in conjunction with whole-genome sequencing (WGS), RNA sequencing (RNAseq) and copy-number variation (CNV) data from The Cancer Genome Atlas (TCGA) 7 , we report the identification of novel noncoding driver mutations for CRC ( Fig. 1, Supplementary Fig. 1 and Supplementary Methods).
We prepared in situ HindIII-digested Hi-C libraries from CRC HT29 and LoVo cell lines, which represent the two major molecular subtypes of CRC-these lines are microsatellite stable (MSS) and microsatellite instable (MSI), respectively. To examine the interactions underlying CREs in CRC, we generated a biotinylated RNA bait library, specifically targeting 19,023 promoter-encompassing HindIII fragments representing 2.3% of all HindIII fragments. We hybridized in situ Hi-C libraries to the RNA baits to capture promoter-associated interactions and sequenced the resulting libraries, from which we identified 96,458 and 118,758 significant contacts in LoVo and HT29 lines, respectively (Supplementary Tables 1-3 ). In both cell lines, the majority of interactions were within topologically associated domains (74% and 83% in HT29 and LoVo cells, respectively; Supplementary Tables 4, 5 and Supplementary Methods). Across 127 cell lines and tissues 17 , the LoVo and HT29 CREs showed strong enrichment of histone marks identified in colonic tissue (Supplementary Table 6 ).
The CREs that were identified by CHi-C were evolutionally conserved (P < 1.0 × 10 ) and enriched for transcription factor binding compared to a random set of genomic fragments (threefold and twofold enrichment for HT29 and LoVo lines, respectively; P < 1.0 × 10 −3 ; Supplementary Fig. 2 ). On the basis of the level of gene expression using RNA-seq for respective target genes, we classified interactions as either active or inactive. As previously documented 8 , a higher frequency of interactions and shorter contact
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Letters NATuRE GENETiCs distances typified promoters of active genes ( Supplementary Fig. 3 ). For genes that were actively transcribed, both promoters and their respective CREs had a higher number of bound transcription factors (P < 2.2 × 10 −16
; Supplementary Fig. 4 ). Moreover, a relationship between elevated gene expression and higher proportion of transcription factors that were bound to CREs was shown, consistent with the functional role of identified CREs ( Supplementary Fig. 5 ).
To investigate the frequency of single-nucleotide variants (SNVs) in CREs delineated by CHi-C, we analyzed colon and rectal adenocarcinoma WGS data from TCGA 7 . After applying stringent quality control and filtering, we retained data on 50 MSS and 12 MSI cancers. The frequencies of SNV base changes were consistent with those previously documented for CRC 18, 19 (Supplementary Fig. 6  and Supplementary Table 7) . Both promoters and CREs showed a significantly lower rate of mutation compared to the genome rate in MSS and MSI cancers (Fig. 2) . This property was also seen after taking into account mutational-signature-derived substitution probabilities (Fig. 2) . This is consistent with previous reports that have shown that functional regulatory regions are less likely to be mutated than non-functional regions of the genome, either as a consequence of selective evolutionary pressure or chromatin accessibility 9, 20 . Because MSI cancers exhibit a significantly higher mutational rate to MSS cancers (median mutations 92,968 and 14,290, respectively) reflective of mismatch repair deficiency 19 (Supplementary Table 8) , we analyzed the two CRC subtypes separately.
To identify non-coding driver mutations in CREs, we integrated results from three driver discovery methods ( Supplementary Fig. 7a ). First, we assessed the transcriptional effects of CRE mutations by comparing the expression levels of respective target genes in mutated and non-mutated cancers 9, 10, 21 . To avoid confounding, cancers in which either the CRE or target gene were subject to CNVs were excluded from the analysis. Second, we tested for regional excess of mutations to provide evidence of positive selection 6, 9, 21, 22 . Third, we assessed the clustering of CRE mutations, as this can be suggestive of events in specific transcription-factor-binding sites 21 .
In MSS cancers, this integrated analysis yielded a CRE interacting with the ETV1 promoter, associated with differential target gene expression and an excess of clustered mutations (Fig. 3a,b , Supplementary Tables 9, 10). On the other hand, no CREs were identified in MSI cancers, and we therefore restricted further SNV analysis to MSS cancers.
We demonstrate the benefit of using CHi-C data to discover non-coding driver mutations by comparing the number of CREs identified by the integrated driver discovery analysis using real and randomized CHi-C data. Specifically, we randomized the CHi-C data by changing the HindIII fragments contacting each gene, sampling from non-interacting fragments within 1 Mb of the gene, while maintaining the number of fragment contacts ( Supplementary Fig. 7b ), and applied the integrated driver discovery analysis in full to each randomized CHi-C data set. Through this procedure, we estimated the empirical false discovery rate (FDR) for the ETV1 CRE to be 0.023 (Supplementary Table 9 and Supplementary Fig. 8) .
ETV1, an oncogene encoding an ETS transcription factor, is altered in several cancers; for example, induced by translocations in Ewing's sarcoma 23 and prostate cancer 24, 25 , amplification in melanoma 26 , and oncogenic dysregulation in gastrointestinal stromal tumors 27, 28 . The ETV1 interaction was confirmed in a panel of MSS CRC cell lines ( Supplementary Fig. 9 ). Considering only the five cancers without a structural variation within 1 Mb of ETV1 (Supplementary Table 11 ), CRE mutations were associated with a fourfold increase in expression of ETV1 compared to non-mutated samples (Fig. 3b) . Additionally, increased ETV1 expression was also seen in two cancer samples without CRE mutations but with ETV1 amplifications (P = 4.1 × 10
; Supplementary Fig. 10a ). Four of the six mutations map proximally to an evolutionary conserved region (Fig. 3a) , and in HT29 cells, each was associated with a threefold increase in luciferase activity, consistent with a regulatory effect ( Fig. 3c and Supplementary Fig. 10b ). The ETV1 CRE, which is proximal to an enhancer H3K4me1 chromatin mark, uniquely interacts with the ETV1 promoter, and the contact is not present in LoVo cells or 17 blood-specific CHi-C data ( Fig. 3a and Supplementary Fig. 11 ). Although the putative enhancer maps within the intron of DGKB, there was no relationship between CRE mutation and DGKB expression ( Supplementary Fig. 12 ). Although no transcription factor was bound to the CRE when analyzing chromatin immunoprecipitation followed by sequencing (ChIP-seq) data in the HT29 cell line, in silico analysis identified numerous potential disrupted transcription-factor-binding sites [29] [30] [31] , including those for BCL6, HNF1A, HNF1B and MAFK (Supplementary Tables 12, 13 and Supplementary Methods). The genes encoding these transcription factors are expressed in colonic tissue 32 ( Supplementary Fig. 13 ). The mutation rates observed in promoters and CREs are shown, as well as the mutation rates that are expected considering the samplespecific occurrence of mutations of each of the 96 substitution types, and the trinucleotide composition of the fragment classes. Box plots denote quartiles, whiskers correspond to the 10th and 90th percentiles. Differences were assessed using a two-sided paired Wilcoxon test.
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We made use of Affymetrix SNP Array 6.0 data from 615 TCGA CRC samples to identify CREs subject to somatic CNVs. CNVpositive CREs were assessed for correlation with expression of their interacting gene, where it was not encompassed by the same CNV, using matched RNA-seq data. The RASL11A promoter showed interactions with a putative enhancer characterized by H3K4me1 marks in both HT29 and LoVo cell lines ( Fig. 4a and Supplementary Fig. 14) . Although a role for RASL11A in tumorigenesis has yet to be defined, it is reported to encode a GTPase chromatin-associated modulator of pre-ribosomal RNA synthesis, acting to facilitate the initiation of transcription by RNA polymerase 1 33 . The RASL11A interaction was confirmed in a panel of MSS CRC cell lines ( Supplementary Fig. 9 ). This CRE was amplified in 12 cancer samples and these had significantly higher RASL11A expression (P = 2.96 × 10 −11
; Fig. 4b and Supplementary Table 14) . Using CRISPR-mediated genome editing, disruption of the interacting CRE was shown to reduce RASL11A expression (Fig. 4c,d and Supplementary Fig. 15 ). USP12 has previously been implicated as a target of this specific CRE 1 . However, after exclusion of samples in which CNVs overlay the gene itself, amplification of the CRE was not associated with differential expression of USP12 or any other gene in the proximity of the CNV segments ( Fig. 4e and Supplementary Table 15 ). One sample that contained a CNV, which overlapped with ETV1, was excluded. Box plots denote quartiles, whiskers correspond to the 10th and 90th percentiles. Differences between samples in which the CRE is mutated (n = 5) and not mutated (n = 41) were assessed by negative binomial test. c, A 946-bp and a 738-bp putative regulatory region containing the six mutations was cloned upstream of the SV40 promoter in the pGL3-promoter vector. The resultant reporter constructs were transiently transfected into HT29 cells for 24 h and the relative luciferase activity was measured for each reporter gene construct. The luminescence ratio of the experimental vector to the Renilla internal control, pRL-TK, was normalized to the backbone pGL3-SV40 promoter vector. Data are mean ± s.e.m. relative to the non-mutated samples from three independent experiments and assessed by two-tailed t-test. RSEM, RNA-Seq by Expectation Maximization; NS, not significant. expression in CRC stratified by CRE amplification status (samples with CNV overlapping RASL11A were excluded). Box plots denote quartiles, whiskers correspond to the 10th and 90th percentiles. Difference between samples in which the CRE is affected (n = 12) and unaffected (n = 522) by a CNV amplification assessed by negative binomial test. c, Schematic representation of the CRISPR-Cas9-mediated deletion using two plasmids expressing different sets of gRNAs. d, RASL11A mRNA levels relative to GAPDH in control and CRISPR-edited cells (CRISPR-1 and CRISPR-2). Differences were assessed by two-tailed t-test from three independent experiments, data are mean ± s.e.m. e, Expression levels of six genes in the proximity of the CRE in the samples in which the CRE is affected or unaffected by CNV amplification (RASL11A unaffected, n = 522; RASL11A affected, n = 12; USP12 unaffected, n = 524; USP12 affected, n = 7; RPL21 unaffected, n = 522; RPL12 affected, n = 12; WASF3 unaffected, n = 523; WASF3 affected, n = 14; GTF3A unaffected, n = 521; GTF3A affected, n = 12; GPR12 unaffected, n = 523; GPR12 affected, n = 13). Samples containing CNVs overlapping the respective gene are excluded from each comparison. Box plots denote quartiles, whiskers correspond to the 10th and 90th percentiles. Differences were assessed by negative binomial test. NS, not significant.
Letters
NATuRE GENETiCs
In HT29 cells, a reduction in endogenous ETV1 and RASL11A levels using short interfering RNA (siRNA) was associated with decreased cell viability and cell proliferation (Fig. 5, Supplementary  Fig. 16 and Supplementary Methods). Using patient outcome data from three independent series totalling 1,282 CRC cases 7, 34, 35 , high levels of ETV1 expression were associated with worse relapse-free and overall survival in a multivariate analysis. Respective meta-analysis hazard ratios associated with elevated expression were 1.32 (95% confidence interval: 1.06-1.64, P = 1.5 × 10 −2 ) and 1.14 (95% confidence interval: 1.03-1.27, P = 9.9 × 10 Table 16 ).
It is arguable that despite high-profile, genuine successes, the number of new driver genes from exome-sequencing projects has been disappointingly small compared to expectations. Many cancers have no observable driver mutation, and the full complement of molecular lesions that are individually necessary, and together sufficient, to cause malignancy are still unknown. The Encyclopedia of DNA Elements (ENCODE) project has proposed that around 80% of the genome contains elements linked to biochemical functionality 36 ; however, others have estimated that the percentage of the human genome that is functional may actually be tenfold lower 37 . Therefore, rather than exploiting the epigenomic landscape, we identified physical contacts between promoters and the interacting CREs, thus reducing the genomic space in which to search for noncoding driver mutations.
In our analysis, we identified a CRE in which mutations were associated with altered expression in CRC. This CRE, interacting with the ETV1 promoter, was mutated in 12% of MSS cancers with the mutations being associated with significant upregulation of ETV1 expression. Although not previously assessed as a determinant of CRC outcome 38 , upregulation of ETV1 was shown to be associated with poor patient prognosis in CRC ( Supplementary  Fig. 17 and Supplementary Table 16 ). The fact that upregulation of ETV1 has previously been linked to reduced survival in other cancers, including gastric cancer, is therefore consistent with increased ETV1 expression inducing aberrant activation of transcriptional programs that broadly govern multiple facets of tumorigenesis. In addition to SNVs having a role in dysregulation of gene expression, we have provided evidence that implicates RASL11A, through amplification of an interacting CRE, in CRC oncogenesis.
We acknowledge that the present analysis has limitations. Firstly, we have used a cellular model to map the CREs, which is unlikely to fully recapitulate the spectrum of pathogenic SNVs and CNVs seen in CRC. Secondly, the low resolution of the defined CNVs has not permitted the study of smaller structural changes, potentially affecting the discovery of deleted or amplified CREs. Thirdly, inevitably as our WGS dataset is modest, this has restricted the study power to identify non-coding drivers. Fourthly, our strategy may not identify genes that are up-or downregulated in most cancers, either when driven by the same or alternative mechanisms.
Accepting these caveats, the generation of a genome-wide promoter-CRE map of CRC using in situ CHi-C has allowed us to perform a highly focused search for functional non-coding mutations. As sequencing costs are significantly reduced, this will afford the opportunity to perform CHi-C directly on WGS samples, thus providing the opportunities to define individualized networks.
In conclusion, our work supports the existence of non-coding drivers for CRC, and more broadly provides a paradigm for using chromosome conformation capture to decode disease-specific regulatory elements. Such discoveries facilitate the identification of novel therapeutic and chemoprevention agents, and classification of patients into molecular subgroups to personalize therapy. For example, it enables the repurposing of ETV1 inhibitors, one of which has been used in a clinical trial for gastrointestinal stromal tumors 28, 39 . URLs. SNPable, http://bit.ly/snpable; NCI Genomic Data Commons Data Portal, https://portal.gdc.cancer.gov/; UCSC Genome Browser, http://hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/ wgEncodeUwRepliSeq/; GTex portal, https://gtexportal.org/.
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Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/ s41588-018-0211-z. were assessed 96 h post-transfection by two-tailed t-test using three independent experiments, data are mean ± s.e.m. c, ETV1 and RASL11A mRNA levels, normalised to GAPDH, after siRNA treatment. Differences were assessed by two-tailed t-test using three independent experiments, data are mean ± s.e.m. RLU, relative light units. Hi-C analysis. In situ Hi-C library preparation. In situ Hi-C libraries were prepared as previously described 14, 16 . In brief, 25 million cells were fixed in 1% formaldehyde for 10 min. Cross-linked DNA was digested by the restriction enzyme HindIII (NEB, R0104). Digested chromatin ends were filled and marked with biotin-14-dATP (ThermoFisher, 19524-016) . The resulting blunt-ended fragments were ligated at 16 °C in the nucleus with T4 DNA ligase (NEB, M0202) to minimize random ligation. DNA was de-crosslinked by proteinase K (Ambion, AM2546) treatment. DNA was sheared by sonication (Covaris, M220) and 200-650-bp fragments were selected. Biotin-tagged DNA was pulled-down with streptavidin beads and ligated with Illumina paired-end adapters (Illumina). Six cycles of PCR were performed to amplify libraries before capture.
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Promoter capture Hi-C library. Promoter capture was based on 32,313 biotinylated 120-mer RNA baits (Agilent Technologies) targeting both ends of HindIIIrestriction fragments that overlap Ensembl promoters of protein-coding, noncoding, antisense, small nuclear RNA, microRNA and small nucleolar RNA transcripts 8 (Supplementary Table 17 ). After library enrichment, a post-capture PCR amplification step was carried out using five amplification cycles. Hi-C and CHi-C libraries were sequenced using HiSeq 2000 technology 16 (Illumina).
Interaction calling. Reads were aligned to the GRCh37 build using Bowtie2 v.2.2.6 40 and identification of valid read pairs was performed using HiCUP v.0.5.9 41 . To call significant contacts, HiCUP output was processed using CHiCAGO v.1.1.8 42 . For each cell line, data from three independent biological replicates were combined to obtain a definitive set of contacts. As previously described, interactions with a score ≥ 5.0 were considered to be statistically significant 42 .
ChIP-seq analysis. ChIP-seq was performed on H3K4me1, H3K9me3, H3K27me3 and H3K36me3 for LoVo cells, and H3K4me1 and H3K9me3 for HT29 cells. Description of the procedures performed can be found in the Supplementary Methods.
Gene expression in LoVo and HT29 cell lines.
Analysis of RNA-seq data on LoVo and HT29 cell lines was performed as previously described 7 . In brief, RNAseq BAM files were downloaded from the Broad Institute Cancer Genomics Hub and analyzed using Cufflinks 43 . Gene-level fragments per kilobase of transcript per million mapped reads (FPKM) counts were derived using GENCODE v.7 annotated mRNA transcripts. Genes with FPKM > 0 were divided into quartiles based on their expression levels, with genes with either 0 FPKM or in Q 1 considered to be inactive, and genes in Q 2 -Q 4 considered to be active 8, 44 . For promoter fragments that were associated with multiple genes, we excluded those with discordant expression.
Annotation of CREs in LoVo and HT29 cell lines.
Reads that did not align uniquely were removed by HiCUP, as they are liable to result in false-positive contacts. The detection of duplicate regions is dictated by genomic build. Therefore, an additional filtering step was performed to remove contacts between fragments mapping to regions that did not map to unique locations in hg38. In brief, hg19/GRCh37 was split into windows of 100 bp before being aligned to hg38 using BWA. A base was considered to be poorly mapped if the majority of reads containing it could be mapped elsewhere in the genome with at most one mismatch or gap, as described in SNPable (see URLs). A contact region was kept if 95% of its constituent bases were not poorly mapped when imposing this metric. Conservation was measured using PhastCons 100-way, considering the average conservation score in 100-bp windows centred on each mutation 45 . The proportion of CREs, not overlapping any coding regions, containing runs of at least eight conserved sites (defined by PhastCons score > 0.5) was compared for the set of LoVo and HT29 CREs to sets of randomly generated fragments. For enrichment calculations, random non-coding regions of the genome were selected matching the identified CREs in fragment size and number, restricting start positions to HindIII sites. Random fragments not overlapping coding regions were resampled 1,000 times. Significance was determined by permutation. We annotated each CHi-C contact that was identified in LoVo and HT29 cells with chromatin features and transcription-factor-binding information. HindIII-interacting fragments were overlaid with histone marks from 127 tissues and cell lines from the ROADMAP Epigenomics project 17 and ChIP-seq experiments 46 (198 and 29 experiments in LoVo and HT29 lines, respectively). Enrichment calculations were performed as described above. The activity of each promoter on its corresponding gene was defined as active or inactive based on the analysis of the matching RNA-seq data. To assess whether there was a relationship between transcription factor binding and expression, we selected only the fragments that interact with promoters of genes belonging to the same expression quartile and allocated transcription factor counts to each CRE as previously described 8 . For promoter fragments associated with multiple genes, expression of all genes was required to be in the same expression quartile. For each expression class, we calculated the proportion of CREs bound by the transcription factor divided by the proportion of all the CREs bound by the same transcription factor. Corresponding values were log 2 transformed 8, 44 .
TCGA colorectal cancer WGS data. WGS data on 50 MSS (36 colon adenocarcinoma (COAD) and 14 rectal adenocarcinoma (READ)) and 12 MSI were obtained from TCGA. Description of these data and mutation calling can be found in the Supplementary Methods.
Mapping non-coding mutations to chromatin-looping interactions. We mapped non-coding mutations to CREs defined by promoter CHi-C generated using the CRC cell lines LoVo and HT29. We annotated only cis-interactions involving a promoter and CRE, excluding trans-interactions and promoter-promoter contacts.
Genome-wide analysis of non-coding mutations. Mutations were allocated to promoters or CREs, and the mutation rates for each fragment class were calculated. Mutation rates were determined as the number of mutations in each fragment class, divided by the size of all the fragments in that class, minus all regions overlapping ORFs, 3′ UTRs, 5′ UTRs and regions with poor mappability (Supplementary Methods). However, mutational signatures have been shown to be critical for estimating purifying selection pressures in cancer somatic mutation data 47 . Taking this into account, the expected mutation rates were estimated considering the sample-specific occurrence of mutations of each of the 96 substitution types previously defined 18 , and the trinucleotide composition of the fragment class.
where i is each of the possible mutation substitutions, u i is the genome-wide number of mutations of type i, v i is the genome-wide number of positions at which mutations of type i can occur, w i is the number of positions in the considered fragment class at which mutations of type i can occur, and y is the size of all fragments in the class. Excluded regions as defined above were not considered.
Integrated analysis of non-coding mutations in CREs.
To identify potential non-coding driver mutations, we integrated three driver discovery methods (Supplementary Fig. 7a ). In this integrated analysis, we first assessed the transcriptional effects of non-coding mutations in CREs, and then tested for an excess in non-coding mutations in CREs. P values computed in these two analyses were adjusted for multiple testing using the Benjamini-Hochberg procedure and CREs were excluded if Q ≥ 0.05 in either analysis. Finally, we assessed the clustering of non-coding mutations in the remaining CREs. P values computed in this clustering analysis were adjusted for multiple testing using the BenjaminiHochberg procedure and CREs were excluded if Q ≥ 0.05. These three driver discovery methods are outlined below.
Testing the transcriptional effects of non-coding mutations in CREs.
Gene expression profiles were based on RNA-seq data from 12 MSI and 50 MSS CRC cases obtained from TCGA that had matched WGS data (gene-level values, accessed 20 January 2017). Differences between samples analyzed on Genome Analyzer and HiSeq were batch-corrected using the ComBat method 48 . To reduce spurious long-distance contacts, interactions were filtered such that the distance between the promoter and CRE was < 1 Mb 49 . For each CRE, samples were divided between non-mutated and mutated based on the presence of non-coding mutations in the corresponding CRE. We tested for differential gene expression between mutated and non-mutated groups using a negative binomial model 9 , implemented in edgeR 50 . Samples with CNVs in either the gene or the related CRE were excluded 9 . CREs were not tested if gene-expression data were not available for the interacting gene, or if the CRE was mutated in fewer than two samples, after the removal of samples with overlapping CNVs. CREs observed to interact with the promoters of multiple genes were tested multiple times. Only CREs interacting with protein-coding genes were tested.
Testing for an excess of non-coding mutations in CREs. We tested regions for an excess of non-coding mutations using a global approach, as previously described 9 . This assumes that the observed number of tumor samples mutated in any specific region follows a binomial distribution, under the null hypothesis that mutations in the region are not under positive selection. Because replication timing affects the Letters NATuRE GENETiCs nucleotide mutation rate, we estimated the mutation rate using data from HeLa, K562, HEPG2, MCF7 and SKNSH cell lines 51 . Again as previously described 9 , we subsetted the genome into 100-kb bins and derived mean replication times for each cell line across each bin. For each interacting region, we then computed a single replication time for each cell line by taking the replication time of the 100-kb bin in which the region is located, or the average replication time if the region spanned multiple 100-kb bins. For each interacting region, we then identified the top 5% of interacting regions with the most similar replication times across cell lines, measured using the Euclidian distance between the vectors of times. The background nucleotide mutation rate q i could then be estimated by dividing the number of mutations in this 5% of interacting regions across all samples by the total number of samples with mutation data and the total effective length of the regions. These results are robust to the percentage of interacting regions that were considered (Supplementary Table 18 ). We excluded the areas of the interacting regions overlapping ORFs, 3′ UTRs, 5′ UTRs and areas with poor mappability (Supplementary Methods). The removal of these areas is incorporated into the effective lengths of the regions. The estimated sample mutation rate s i is dependent on the estimated nucleotide mutation rate q i of the region under the null hypothesis, and the effective size of the region L i :
Mutational excess P values follow discrete distributions and we therefore computed randomized P values for each region i using the right tail masses 22 :
where n is the total number of cancers, k the number of cancers with ≥ 1 mutation in region i and p i is the corresponding randomized P value. Inflation-factor estimation was conducted with the regression method implemented in the GenABEL R package 52 . Using all P values indicated that the statistics generated under this model were weakly inflated (λ 100% = 1.08; Supplementary Fig. 18 ).
Testing for clustering of non-coding mutations in CREs.
We evaluated whether CRE mutations cluster using the weighted average proximity (WAP) method
where d is the linear genomic distance between mutations i and j, and t is a weighting constant. As previously described 21 , we used t = 6, as this reflects the typical size of the core of transcription-factor-binding motifs. Statistical significance of each WAP score was determined by permuting mutation positions 10,000 times, while maintaining the size of the CRE and excluding regions overlapping ORFs, 3′ UTRs, 5′ UTRs and regions with poor mappability (Supplementary Methods). Empirical P values were calculated as the proportion of mutation permutations with WAP scores that were equal to or greater than the WAP score computed using the observed mutation positions.
Empirical FDR estimation.
We estimate an empirical FDR for the identified CRE by comparing the number of results yielded by the integrated driver discovery analysis when using real and randomized CHi-C data ( Supplementary Fig. 7b ). CHi-C data were randomized by changing the HindIII fragments contacting each gene, by sampling from non-interacting fragments (CHiCAGO score < 1) within 1 Mb of the gene, while maintaining the number of fragment contacts. The integrated driver discovery analysis was then applied in full to each randomized CHi-C dataset. The expected number of false discoveries was estimated as the mean number of CREs yielded by the integrated driver discovery analysis across 1,000 randomized CHi-C datasets. The empirical FDR was estimated as the ratio of false discoveries to the total number of CREs detected when the real CHi-C data were used 53 .
Relationship between gene expression and CNV at CREs. To identify CNVs overlapping CREs, we utilized Affymetrix Genome-Wide Human SNP Array 6.0 copy-number data from the TCGA COAD study of 450 cancers and the READ study of 165 cancers. Focal deletions and amplifications were defined as abs(log 2 ratio) ≥ 0.3 54 and size < 3 Mb 55 . We analyzed matched RNA-Seq by Expectation Maximization (RSEM) RNA-seq and CNV data from the TCGA COAD and READ studies (n = 606). To identify cancers with deleted or amplified CREs correlated with expression of an interacting gene, we applied the following filters to each CRE-promoter interaction: first, we identified cancers with a focal amplification or deletion of the CRE; second, we excluded cancers with evidence of a CNV at the interacting gene (a GISTIC2 score ≠ 0); third, we restricted our analysis to CREs affected in ≥ 7 samples (representing 1% of samples). We compared gene expression between affected and unaffected samples using edgeR 50 with default parameters. Samples were considered unaffected if there was no evidence of a CNV at the CRE (a GISTIC2 score = 0). Genes that showed differential expression between affected and unaffected samples and an absolute correlation coefficient ≥ 0.4 between GISTIC2 score and gene expression value were taken forward for further analysis.
Relationship between CRE mutation and translocations and inversions. Because translocations and inversions can dysregulate gene expression, we examined whether there were any translocations and inversions in the proximity of mutated CRE target genes. Translocation and inversion breakpoints, called using dRanger 56 , were downloaded from the International Cancer Genome Consortium Data Portal (accessed 30 July 2017).
Genomic DNA extraction. Cells were collected, washed twice in PBS and genomic DNA was extracted using a QIAamp DNA Blood Mini Kit (Qiagen). The DNA concentration was measured using Qubit dsDNA BR Assay (ThermoFisher Scientific).
Chromosome conformation capture (3C) validation. 3C-PCR was used to validate ETV1 and RASL11A interactions in a panel of colon-derived MSS CRC cell lines. Two cell culture replicates of in situ 3C libraries were prepared using HT29, SW480, SW1116, Caco2, HT115 and SW948 cells. Cell pellets were cross-linked, digested with HindIII, and ligated using the same conditions described in the Hi-C section, excluding the biotin step. Digestion and ligation efficiency were assessed on agarose gel before proceeding to phenol-chloroform purification. Ligation primer pairs were designed to amplify ligation junctions between the promoter and interacting HindIII fragment (promoter-CRE) (Supplementary Table 19 ). Genomic DNA was used as control for the possibility that amplification across ligation junctions could be the result of structural variations. To prove fidelity of genomic DNA as template, primer pairs were also designed to amplify the genomic region around each of the ligation primers (Supplementary Table 19 ). All primers were designed using Primer3. Regions were amplified using a Multiplex PCR Kit (Qiagen); 100 ng template DNA was amplified using the following procedure: initial 15 min denaturation at 95 °C followed by 38 cycles of 95 °C for 30 s, 60 °C for 90 s, 72 °C for 45 s. Subsequently, 5 μ l of each PCR reaction was visualized on 2% agarose gels stained with ethidium bromide. The identity of the fragments visualised on agarose gels was confirmed by Sanger sequencing (Supplementary Fig. 9 ).
Plasmid construction and luciferase assays. The length of the full region spanning the six mutations is over 1.2 kb and therefore a 1.6-kb fragment would have been required to ensure that all mutations mapped centrally within the fragment. Because of the length of this region, we decided to clone the two fragments separately, so that we could clone inserts with a length of < 1 kb. A 946-bp and a 738-bp genomic region within the ETV1 CRE was amplified from human genomic DNA using primers described in Supplementary Table 19 . Gelpurified PCR products (Qiagen) were A-tailed using 2U Thermoprime DNA polymerase (ThermoFisher Scientific) and 200 µ M dATP for 30 min at 70 °C. The products were cloned into the PCR8/GW/TOPO vector and single bacterial colonies containing the vector were cultured and purified (Qiagen Mini-prep Kit). The six somatic mutations were generated with site-directed mutagenesis (Agilent Quick Change XL kit) using primers detailed in Supplementary Table  19 . Changes introduced by site-directed mutagenesis were confirmed by Sanger sequencing. Regulatory regions with both non-mutated and mutated sequences were cloned into pGL3 luc2-promoter vector (Promega) using Gateway LR Clonase II technology (ThermoFisher Scientific). The reporter constructs were transfected into HT29 cells using Lipofectamine 2000 (ThermoFisher Scientific). In brief, 7.5 × 10 5 cells were seeded and transfected the following day with 3 μ g reporter constructs and 150 ng of internal control plasmid (pRL-TK). Transiently transfected cells were cultured for 24 h, after which the luciferase assay was performed using the Dual-Luciferase Reporter Assay System (Promega) as per the manufacturer's recommendations. Firefly and Renilla luciferase luminescence were measured in triplicate on a Fluoroskan Ascent FL plate reader (ThermoFisher Scientific). The ratio of luminescence from the experimental reporter to the luminescence from the control reporter was calculated for each sample, defined as the relative luciferase activity.
CRISPR-Cas9-mediated enhancer disruption. Two set of guide RNAs (gRNAs) were designed to target the CRE interacting with the RASL11A promoter using E-CRISP 57 . To check that the required PAM sequence was not altered in the HT29 cell line, the region to which the gRNAs were mapped was Sanger sequenced using genomic DNA. Each set of gRNAs was designed to target upstream and downstream of the enhancer region, and cloned in one plasmid expressing the
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Cas9 gene and the RFP marker. A control plasmid was generated containing all the elements of the targeting plasmids other than the gRNAs. Custom plasmids were obtained from ATUM. gRNA sequences are reported in Supplementary Table 19 . HT29 cells were seeded at 7.5 × 10 5 density in six-well plates and transfected the following day with 10 µ l of Lipofectamine 2000 (ThermoFisher Scientific) and 2 µ g of the respective plasmids. After 48 h of transfection, cells expressing RFP were selected using FACSAriaIIμ cell sorter (BD Biosciences) and seeded into a 24-well plate. After 2-3 weeks, cells were collected to extract either genomic DNA to confirm the enhancer deletion, or total RNA to assess gene expression. Primers used to assess the deletion are listed in Supplementary Table 19 .
Cell viability assays. In 96-well plates, cells were transfected with siRNAs and incubated with CellTiterGlo reagent according to the manufacturer's protocol (CellTiterGlo Luminescent Cell Viability Assay kit, Promega). For each experiment, luminescence was measured in triplicate at 0, 24, 48 and 72 h posttransfection using a Fluoroskan Ascent FL plate reader (ThermoFisher Scientific) (Supplementary Fig. 16 ).
Real-time cell proliferation assays. After siRNA transfection, 96-well plates were introduced into an Incucyte Zoom imaging system (Essen BioScience) enclosed in an incubator at 37 °C and 5% CO 2 humidified air. Each well was imaged by phase contrast every 4 h for 92 h. Images were collected and the percentage of confluence was determined using software provided by the manufacturer. Confluence was averaged over four fields of view per well. Data were normalized to the first scan to account for differences in seeding across individual samples and across replicates.
Statistical analyses. The observed and expected mutation rates in promoters and CREs were compared using two-sided paired Wilcoxon rank-sum tests. CHi-C interactions involving promoters of active and inactive genes were compared using two-sided Wilcoxon rank-sum tests 8 . For luciferase, cell viability and real-time cell proliferation assays, statistical significance was calculated using two-tailed Student's t-tests over three independent experiments. The Benjamini-Hochberg procedure was used to adjust for multiple testing, unless otherwise specified.
